From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.
In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.
A nearly decade-long observational follow-up found continued slowing of axial elongation into late adolescence, while refractive outcomes remained less consistent.
Nearly 10 years of observational follow-up suggested sustained axial-length slowing, although refractive findings were less consistent and comparisons relied on statistical modeling.
Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.
An artificial intelligence–based optical coherence tomography pathway met noninferiority criteria for false-positive diabetic macular edema referrals and was associated with fewer referral decisions in a randomized clinical trial.
This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.